Free Trial

CalciMedica (CALC) Competitors

CalciMedica logo
$3.20 +0.15 (+4.92%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$3.22 +0.01 (+0.47%)
As of 10/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CALC vs. MIST, SLS, TARA, AVTX, NLTX, MCRB, CTOR, GNLX, CLLS, and CCCC

Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Milestone Pharmaceuticals (MIST), SELLAS Life Sciences Group (SLS), Protara Therapeutics (TARA), Avalo Therapeutics (AVTX), Neoleukin Therapeutics (NLTX), Seres Therapeutics (MCRB), Citius Oncology (CTOR), Genelux (GNLX), Cellectis (CLLS), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.

CalciMedica vs. Its Competitors

Milestone Pharmaceuticals (NASDAQ:MIST) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 41.6% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company Overall Sentiment
Milestone Pharmaceuticals Neutral
CalciMedica Neutral

CalciMedica has lower revenue, but higher earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Pharmaceuticals$1M179.33-$41.52M-$0.84-2.51
CalciMedicaN/AN/A-$13.70M-$1.60-2.00

Milestone Pharmaceuticals currently has a consensus target price of $4.50, indicating a potential upside of 113.27%. CalciMedica has a consensus target price of $16.00, indicating a potential upside of 400.00%. Given CalciMedica's higher probable upside, analysts clearly believe CalciMedica is more favorable than Milestone Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
CalciMedica
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

CalciMedica's return on equity of -206.51% beat Milestone Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone PharmaceuticalsN/A -1,672.29% -83.09%
CalciMedica N/A -206.51%-103.81%

Milestone Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Summary

Milestone Pharmaceuticals and CalciMedica tied by winning 6 of the 12 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALC vs. The Competition

MetricCalciMedicaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$44.71M$3.36B$6.13B$10.58B
Dividend YieldN/A2.28%5.67%4.69%
P/E Ratio-2.0022.2886.9626.71
Price / SalesN/A458.33605.32131.81
Price / CashN/A47.8637.9061.31
Price / Book2.999.9312.556.55
Net Income-$13.70M-$52.80M$3.31B$277.50M
7 Day Performance3.90%5.22%4.28%2.42%
1 Month Performance3.90%10.61%6.90%8.63%
1 Year Performance-26.58%25.03%70.54%31.60%

CalciMedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALC
CalciMedica
2.2754 of 5 stars
$3.20
+4.9%
$16.00
+400.0%
-26.6%$44.71MN/A-2.0030
MIST
Milestone Pharmaceuticals
1.8172 of 5 stars
$2.00
-1.5%
$4.50
+125.0%
+40.7%$169.98M$1M-2.3830Positive News
SLS
SELLAS Life Sciences Group
2.2431 of 5 stars
$1.61
+3.2%
$7.00
+334.8%
+48.4%$169.53M$1M-5.0310News Coverage
Positive News
Short Interest ↓
TARA
Protara Therapeutics
1.5494 of 5 stars
$4.35
-1.4%
$19.60
+350.6%
+177.1%$167.82MN/A-2.6930Gap Up
AVTX
Avalo Therapeutics
3.2923 of 5 stars
$12.71
-2.4%
$31.67
+149.1%
+37.2%$167.16M$441K0.0040Short Interest ↑
High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$17.71
-0.6%
N/A-54.0%$166.44MN/A-5.6990High Trading Volume
MCRB
Seres Therapeutics
2.4313 of 5 stars
$19.24
+2.9%
$14.33
-25.5%
+21.3%$163.62MN/A-4.18330Positive News
CTOR
Citius Oncology
3.2306 of 5 stars
$2.03
flat
$6.00
+195.6%
+58.8%$159.09MN/A0.00N/AShort Interest ↓
Gap Down
GNLX
Genelux
1.6137 of 5 stars
$4.20
-1.2%
$20.33
+384.1%
+76.6%$158.65MN/A-4.8810News Coverage
Positive News
CLLS
Cellectis
1.7773 of 5 stars
$2.85
+0.4%
$4.00
+40.4%
+84.8%$158.40M$49.22M-3.48290Positive News
CCCC
C4 Therapeutics
3.7278 of 5 stars
$2.22
-0.4%
$8.50
+282.9%
-57.8%$158.00M$35.58M-1.41150Positive News

Related Companies and Tools


This page (NASDAQ:CALC) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners